The validity ofPfLIgG levels as a proxy measure for the number of malaria episodes during the nonobservation period could be demonstrated by the positive correlation betweenPfLIgG levels and the malaria incidence rates during the 21-month observation period, showing a similar pattern in each of the study arms (Figure 1A)

The validity ofPfLIgG levels as a proxy measure for the number of malaria episodes during the nonobservation period could be demonstrated by the positive correlation betweenPfLIgG levels and the malaria incidence rates during the 21-month observation period, showing a similar pattern in each of the study arms (Figure 1A). malaria transmission, where parasitic resistance to SP is not high [1]. The strategy behind IPTi is to administer full courses of antimalarials alongside routine vaccinations of the Expanded Program on Immunization of the WHO, regardless of whether an infant is parasitemic [2]. A pooled analysis of 6 trials using SP for IPTi in 4 African countries demonstrated a protective efficacy of 30.3% against uncomplicated malaria, 21.3% against anemia, and 22.9% against all-cause hospital admission during the first year of Nes life [3]. In another trial from northern Tanzania comparing various drugs for IPTi, SP failed to provide protective efficacy due to preexisting drug resistance [4]. So far, however, long-term effects of Chitosamine hydrochloride IPTi such as possible extended efficacy or rebound phenomena are largely unknown. During the first SP-IPTi trial in Tanzania, an extended protective antimalarial effect beyond the duration of the pharmacological effects was described [5]. A detailed analysis of data from 2 studies from Ghana and Gabon suggested that SP-IPTi works mainly through a therapeutic and prophylactic effect over 3060 d after drug application and that sustained effects beyond posttreatment prophylaxis might be very low [6]. In at least 3 of the SP-IPTi trials, distinct rebound effects of anemia, high-density parasitemia, or hospital admissions were reported [79]. Nevertheless, results from an extended follow-up study in Gabon do not appear to support the concept of rebound effects after SP-IPTi [10]. To assess the long-term effects of SP-IPTi, a cross-sectional follow-up survey of former study participants was performed 4 years after initial recruitment [7]. AntiPlasmodium falciparumlysate immunoglobulin G antibody (PfLIgG) levels were used as a proxy measure for the frequency of preceding malaria episodes, as has been shown to be expedient in this setting [11]. == METHODS == The follow-up survey took place Chitosamine hydrochloride in the same 9 villages (Afigya Sekyere district, Ashanti region, Ghana) where the placebo-controlled, double-blind, randomized SP-IPTi trial was performed (registered atwww.ClinicalTrials.gov;NCT00206739). Recruitment in the present study was between September and November 2007, which was 3 years after the unblinding in the IPTi trial. In the study area, there is intense perennial malaria transmission. Documentation of medical histories, physical examinations, blood sampling, and laboratory testing were performed following the same standard operating procedures as described previously [7,11]. Axillary temperature of 38.0C or fever during the preceding 48 h reported by caretakers without being asked, accompanied by asexualP. falciparumparasitemia of >500 parasites/L, was defined as malaria. Both attendance at outpatient clinics and admission to hospital in the time between the original trial and the current survey were assessed by interviewing caretakers and checking medical records. Children with uncomplicated malaria were treated with artesunate (4 mg/kg/d) plus amodiaquine (10 mg/kg/d) for 3 d according to national guidelines.PfLIgG levels were measured by enzyme-linked immunosorbent assay and expressed in relative units (RUs) as described previously [11]. Methods ofPfLIgG assessment were identical in the IPTi trial and in the present study but were performed independently at different time points. Analyses were performed using Stata/IC software (version 10.0; StataCorp). Variables were compared between study arms by a contingency test (2) for proportions and a nonparametric test (Wilcoxon rank-sum) for continuous variables. The Spearman rank correlation test was used to correlatePfLIgG levels at age 24 months with malaria incidence rates during the first 2 years of life (original trial) and withPfLIgG levels measured at the time of the current survey. The risk of being parasite positive at the time of the survey in dependence on rates of parasitemia during the original trial was calculated using a bivariate logistic regression model, testing SP treatment as a possible confounding covariate.Pvalues <.05 were considered significant. The aim and principles of the study were explained to the caretakers of participants, and informed consent was thumbprinted or signed by individuals caregivers relative to the Declaration of Helsinki. The analysis was authorized by the Committee on Human being Study Publication and Ethics of the institution of Medical Technology from the Kwame Nkrumah College Chitosamine hydrochloride or university of Technology and Technology, Kumasi, Ghana. == Outcomes == A lot more than 4 years after preliminary recruitment, 730 (82.3%) from the 887 kids who had completed the initial IPTi trial could possibly be included. Baseline features were identical in both research arms (Desk 1). Altogether, 45 (6.2%) kids had uncomplicated malaria.